LP
MACK

LMR Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

LMR Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,274
Closed -$102K – 566
2018
Q3 		$102K Sell
24,274
-30,265
-55% -$128K 0.01% 325
2018
Q2 		$211K Buy
+54,539
New +$362K 0.01% 406

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMR Partners's MACK Position: Q4 2018 in Review

LMR Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 24,274 shares — an estimated $102K sold.

LMR Partners first reported a position in MACK in Q2 2018 and held it in 2 quarters. The position peaked at $211K in Q2 2018. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

  • LMR Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • LMR Partners sold 24,274 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $102K.
  • LMR Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • LMR Partners's Merrimack Pharmaceuticals, Inc. position peaked at $211K in Q2 2018.
  • 56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on LMR Partners's 13F filing for Q4 2018, filed 14 Feb 2019.